Memantine Eg (Memantine Hydrochloride)

Memantine works by binding to the NMDA receptor’s ion channel at a site separate from the glutamate binding site. This non‑competitive antagonism limits excessive calcium entry into neurons, reducing excitotoxic damage while allowing normal neurotransmission, which supports neuronal health in Alzheimer’s disease.

The specific dose of memantine is individualized by the prescribing clinician based on the patient’s condition, renal function, and tolerability. The prescriber determines the appropriate starting dose, titration schedule, and maintenance dose according to current clinical guidelines.

Safety data for memantine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers usually advise a careful risk‑benefit assessment before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the Memantine Eg product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are cholinesterase inhibitors. Memantine is typically used for moderate to severe disease and may be combined with a cholinesterase inhibitor for additive benefit, offering a different mechanism of action.

Memantine Eg should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

Memantine Eg is administered orally, usually as a tablet or capsule, and is taken with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and swallow the tablet whole with water.

Serious risks include the potential for seizures, severe allergic reactions such as anaphylaxis, and rare neuropsychiatric events like hallucinations or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms while on memantine.

Memantine is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, as these conditions may increase the risk of adverse effects.